MPNUniversity.tv

Click here to view additional programs >>

Holding Court in MPN: Does Distinguishing Between WHO 2016 Prefibrotic (prePMF) and ET Matter? | Moderator (Judge): Srdan Verstovsek, MD, PhD

Holding Court in MPN: Is the Current PV Assessment System Adequate to Predict Outcomes and Guide Therapy? | Moderator (Judge): Srdan Verstovsek, MD, PhD

Holding Court in MPN: Should Low-risk MF Patients Be Treated With a JAK Inhibitor Upfront, or Save It for Later? | Moderator (Judge): Srdan Verstovsek, MD, PhD

Holding Court in MPN: In PV, Should JAK Inhibitor Therapy Be Restricted to After Failure of Hydroxyurea? | Moderator (Judge): Srdan Verstovsek, MD, PhD

Myeloproliferative Neoplasms: Contemporary Management and Unmet Needs | Naval Daver, MD

Case 12: A Myelofibrosis Patient is Thinking of Having a Splenectomy For Her Painful Splenomegaly | Olatoyosi Odenike, MD
Otitolola Arterbery, MSN, RN, OCN
Jeffrey Bryan, PharmD, RPh

To expand the available knowledge of myeloproliferative neoplasms (MPNs), MPNUniversity supports an online community of experts and a forum for discussion.

Srdan Verstovsek, MD, PhD
Professor, Department of Leukemia,
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

John O. Mascarenhas, MD, MS
Assistant Professor Medicine,
Hematology and Medical Oncology
Mount Sinai School of Medicine
New York, New York

Jeffrey C. Bryan, PharmD
Clinical Pharmacy Specialist,
Department of Leukemia,
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Otitolola G. Arterbery, MSN, RN, OCN
Research Nurse Specialist,
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas


How common is it that two members of the same family to contract MPNs? \| It is not uncommon to find patients diagnosed with a myeloproliferative neoplasm (MPN) to have other family members who have a similar diagnosis...
More >>


Do the positive results of the Comfort-1 study regarding prolonged longevity and attentuation of symptoms provide rationale to be a universal treatment for myelofibrosis? Also, is panobinostat close to approval by a regulatory authority anywhere? \| Prolonged survival of patients initially randomized to ruxolitinib vs. those randomized to placebo or best available therapy...
More >>


If a patient has erythrocytosis e.g. a Hgb in a male of >18.5 but on further evaluation the patient does not have PV or other MPN is there a benefit to therapeutic phlebotomy? If yes at what Hgb do you initiate it? What is your target in this situation? \| One would usually like to find a cause of abnormally high Hgb...
More >>


In a patient with high risk ET- what platelet count is your trigger to initiate cytoreductive therapy? Once you start cytoreductive therapy what is the target platelet count that you are aiming to reach? \| Risk assessment in ET is based on the presence of age over 60...
More >>


What is acute leukemia? \| What is acute leukemia? Acute leukemia is a rapidly-progressing type of cancer where blood cells grow out of control...
More >>


If a patient with a clinically significant comorbidity must continue taking a drug that alters CYP3A4-mediated metabolism, can he/she still be given ruxolitinib for newly diagnosed PMF? \| Ruxolitinib is metabolized primarily...
More >>


Is ruxolitinib an appropriate therapy in patient with MF without significant splenomegaly? \| Yes. Both of the COMFORT studies required that patients had significant splenomegaly...
More >>


How common is the JAK2 V617F mutation in essential thrombocythemia, and does it affect patient outcome? \| In a recent database study of patients with WHO-defined essential thrombocythemia...
More >>


Why do so many patients with polycythemia vera have pruritus? \| Pruritus is very common in patients with polycythemia vera (PV) (about 40%)...
More >>


Are there certain subsets of MF patients who derive more (or less) clinical benefit from ruxolitinib therapy? \| The clinical benefits of ruxolitinib relative to placebo, as demonstrated in the COMFORT-I study...
More >>


Since MPNs have the potential to progress to acute myeloid leukemia (AML), are JAK kinase inhibitors being studied in post-MF AML? \| MPNs do represent a disease continuum. A phase II study evaluated ruxolitinib in...
More >>

TV - Your Peer Network

The MPN University Allied Health Resource Center was developed to provide information and tools for allied health professionals to aid in the diagnosis, treatment and management of patients with MPN and related disorders. The Reource Center was funded through an unrestricted educational grant from Incyte Corporation.

Allied Health Steering Committee

Jeffrey C. Bryan, PharmD
Clinical Pharmacy Specialist,
Department of Leukemia,
The University of Texas,
MD Anderson Cancer Center
Houston, Texas

Otitolola G.Arterbery, MSN, RN, OCN
Research Nurse Specialist,
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas

IMPACTLive MPN, is a series of FREE, LIVE upon-request, CE-certified programs, designed with your schedule and educational interests in mind. Led by a renowned faculty, these lectures focus on ‘hot topics’ in MPN science, as well as novel approaches to the care of patients with MPN.

Learn More

You can create your own custom event or join one that is already scheduled in your area.



MPNUniversity.tv is a member of the Oncology.TV family of oncology medical education websites. MPNUniversity.tv offers specialists, primary care physicians, and other healthcare professionals the timeliest comprehensive and relevant clinical information to improve patient care. We provide medical education (both free CE and non CE, including interactive case based presentations), news and information about Myeloproliferative Neoplasms (MPNs).